

## Table of Contents

|           |  |     |
|-----------|--|-----|
| Chapter 1 | Regulatory Oversight of Radiological Health and Imaging Devices.....               | 1   |
|           | <i>Eriko Yoshimaru, PhD</i>  |     |
| Chapter 2 | Diagnostic X-Ray Imaging .....   | 15  |
|           | <i>Yu-Wen Wang, PhD, Sharon Murphy, MBA, Esther Akinnagbe-Zusterzeel, MS</i>       |     |
| Chapter 3 | Magnetic Resonance Imaging Systems .....   | 39  |
|           | <i>Jana G. Delfino, PhD; Ningzhi Li, PhD; Rongping Zeng; PhD; Terry Woods, PhD</i> |     |
| Chapter 4 | Mammography in the US: The Mammography Quality Standards Act and Beyond.....       | 57  |
|           | <i>Kish Chakrabarti, PhD, FAAPM; Ruth Fischer, MHSA; Jay Vaishnav, PhD, RAC</i>    |     |
| Chapter 5 | Diagnostic Ultrasound Systems .....  | 69  |
|           | <i>Yu-Wen Wang, PhD; Ninad Gujar, PhD, MBA; Yuan Fang, PhD, MBA, PEng, RAC-US</i>  |     |
| Chapter 6 | Radiation Therapy and Nuclear Medicine: An Overview of Current Trends.....         | 79  |
|           | <i>Peter Coronado, MS, RAC; Jay Vaishnav, PhD, RAC; Amarjeet Bhullar, PhD, PSM</i> |     |
| Chapter 7 | The Regulation of Software in the Radiological Health Space .....                  | 97  |
|           | <i>Catherine Lowe; Qin Li, PhD</i>   |     |
| Chapter 8 | Artificial Intelligence-based Software .....                                       | 113 |
|           | <i>Gopal Abbineni, MS, PhD; Hortense Allison, MS, MBA</i>                          |     |

### Tables

|            |   |    |
|------------|---|----|
| Table 1-1. | List of CDRH Review Offices.....  | 2  |
| Table 1-2. | Summary of Premarket Submission Types.....  | 5  |
| Table 1-3. | Fiscal Year 2022 MDUFA Cohorts by CDRH's OHTs.....  | 7  |
| Table 1-4. | Record and Reporting Requirements by Product – 21 CFR §1002.1 (Table 1) .....   | 10 |
| Table 2-1. | Applicability of International Electrotechnical Commission (IEC) Standards to Specific Medical Device Classifications .....   | 17 |
| Table 2-2. | Electronic Product Radiation Control (EPRC) Requirements That Would Not be Deemed to be Met Based Solely on Conformity to International Electrotechnical Commission (IEC) standards ..... | 18 |
| Table 2-3. | General Comparison Between Film-Based Radiography, Computed Radiography (CR), and Direct Digital Radiography (DDR) .....  | 23 |

|            |  |     |
|------------|--|-----|
| Table 2-4. | Selected Device Problems Reported in the FDA’s Medical Device Reporting (MDR) Database Between 2018 and 2023 .....   | 34  |
| Table 2-5. | Summary of the FDA’s Post-Marketing Surveillance System for Diagnostic X-ray Systems .....   | 35  |
| Table 3-1. | Ten-Year Review of MRI Adverse Events: Breakdown by Category .....   | 50  |
| Table 4-1. | Technical specifications of the five commercial DBT systems .....  | 63  |
| Table 5-1. | Well-established ultrasound modes of operation utilizing longitudinal waves .....  | 72  |
| Table 5-2. | Acoustic Output Exposure Levels for Diagnostic Ultrasound Devices.....   | 75  |
| Table 6-1. | Product Codes Under 21 CFR §892.5050 (Medical Charged-particle Radiation Therapy System) and 21 CFR §892.5060 (Fludeoxyglucose F18-Guided Radiation Therapy System)..... | 85  |
| Table 6-2. | Product Codes Under 21 CFR §892.5730 (Radionuclide Brachytherapy Source) .....   | 87  |
| Table 7-1. | Radiological Health Software Regulations, Product Codes, Device Types, Device Classes .....  | 99  |
| Table 7-2. | Consensus Standards and Other Documents Relevant to Radiological Health Software .....   | 101 |
| Table 7-3. | Possible IMDRF Framework for Risk Categorization of SaMD .....   | 111 |
| Table 8-1. | Terms, Abbreviations and Definitions Related to AI and ML Technologies .....   | 116 |
| Table 8-2. | Examples of Key Performance Metrics Evaluated by the FDA During the Clearance of recent Computer-Assisted Detection (CADE) Devices .....                                 | 123 |
| Table 8-3. | Examples of FDA-Cleared AI/ML Devices for Cardiology .....   | 124 |
| Table 8-4. | Good Machine Learning Practice for Medical Device Development: Guiding Principles.....   | 126 |
| Table 8-5. | Key Considerations for Successful CAD Regulatory Documentation .....   | 127 |
| Table 8-6. | Summary of Key Digital Health Activities .....   | 132 |

## Figures

|             |  |     |
|-------------|--|-----|
| Figure 2-1. | The OHT8B is Responsible for Reviewing Radiological Imaging Device Technologies..                        | 16  |
| Figure 2-2. | Typical System Configuration Integrated with the Auto ROI Components .....                               | 29  |
| Figure 3-1. | Magnetic Resonance Diagnostic Device Regulation 21 CFR §892.1000.....                                    | 40  |
| Figure 3-2. | Understanding MRI Safety Labeling.....   | 43  |
| Figure 3-3. | MRI Scanning Tips for Implants.....  | 44  |
| Figure 3-4. | MRI Burn Prevention .....  | 45  |
| Figure 5-1. | The OHT8C is Responsible for Reviewing Diagnostic Ultrasound Systems .....                               | 70  |
| Figure 6-1. | Simplified Schema of a Typical Radiotherapy Clinical Workflow in a Patient Diagnosed with Cancer.....    | 80  |
| Figure 6-2. | Gantry-Based Radiotherapy System .....   | 81  |
| Figure 6-3. | Brachytherapy for Prostate Cancer .....  | 82  |
| Figure 6-4. | Number of 510(k) Approvals Per Year in the Main Product Codes Related to Radiation Therapy Devices.....  | 86  |
| Figure 6-5. | Number of 510(k) Approvals Per Year in the Main Product Codes Related to Brachytherapy .....             | 88  |
| Figure 6-6. | Components of a Nuclear Medicine Device .....  | 90  |
| Figure 7-1. | General Overview of the FDA’s Thinking on Whether a Clinical Decision Support Software is a Device ..... | 104 |
| Figure 7-2. | OTS and SOUP are not equivalent. A software component can be OTS but not SOUP, and vice versa.....       | 106 |
| Figure 7-3. | Healthcare and Public Health Sector Coordinating Council (HSCC) Product Security Framework .....         | 108 |

|  |     |
|--|-----|
| Figure 7-4. Application of Cybersecurity Principles and How They Impact the Risk Management Process.....   | 109 |
| Figure 7-5. Health Software Life Cycle Processes.....  | 110 |
| Figure 8-1. Schematic Representation of (a) The Number of FDA Approvals and Clearances Per Year and (b) The Number of Device Authorizations by FDA Regulation Panel as of 31 December 2022 .....   | 114 |
| Figure 8-2. A Brief Chronology of Computer-Assisted Device Evolution .....   | 118 |
| Figure 8-3. Schematic Representation of Number of Computer-Assisted Detection Clearances by (a) FDA Category and (b) by Year Cleared According to Data From the American College of Radiology’s Data Science Institute – AI Central..... | 119 |
| Figure 8-4. Overview of Computer-Assisted Diagnosis Applications.....  | 121 |
| Figure 8-5. Schematic Representation of Various Development Stages in SaMD .....   | 125 |

## Author Acknowledgments

RAPS thanks the following subject matter experts for sharing their experience and knowledge and volunteering their time to contribute to *From X-Rays to AI: Navigating US Regulations in Radiological Health*.

### Editors

**Yuan Fang, PhD, MBA, PEng,  
RAC-US**

Divisional Vice President,  
Global Strategic Regulatory  
Abbott Laboratories Inc.

**Jay Y. Vaishnav, PhD,  
RAC-Devices**

Director of Regulatory Affairs  
RefleXion Medical

### Authors

**Gopal Abbineni, PhD, MS**  
Director, Regulatory Affairs  
Bayer Pharmaceuticals

**Esther Akinragbe-Zusterzeel,  
MS**

Biomedical Engineer  
Food and Drug Administration

**Hortense Allison, MS, MBA,  
RAC-US**

Vice President and Head of  
Regulatory Affairs  
Bayer Pharmaceutical

**Amarjeet S. Bhullar, PhD,  
PSM**

Medical Physicist  
Food and Drug Administration

**Kish Chakrabarti, PhD**

Senior Expert Regulatory  
Scientist (Retired)  
Food and Drug Administration

**Peter Coronado, MS, RAC-US**

President and Principal  
Consultant

Agile Regulatory Consulting

**Jana G. Delfino, PhD**

Deputy Division Director  
Food and Drug Administration

**Ruth Fischer, MHSA**

Assistant Director for Guidance  
Management (Retired)

Food and Drug Administration

**Ninad A Gujar, PhD, MBA,  
MS**

Vice President  
Samsung Healthcare  
(NeuroLogica & Boston  
Imaging)

**Ningzhi Li, PhD, MS**

Senior Reviewer  
Food and Drug Administration

**Catherine Lowe**

Director/Consultant  
LoweRiskQA Consulting Inc.

**Sharon L. Murphy, MBA**

Vice President Regulatory  
Affairs  
ZimmerBiomet

**Yu-Wen Wang, PhD**

Regulatory Affairs and Quality  
Assurance Consultant

**Terry Woods, PhD**

Director, Standards and  
Conformity Assessment  
Program  
Food and Drug Administration

**Eriko Yoshimaru, PhD**

**Rongping Zeng, PhD**

Food and Drug Administration